This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bluebird-Medigene TCR Candidate
Drug Names(s): Bluebird-Medigene TCR Candidate
Description: Bluebird bio and Medigene are developing a TCR Candidate under a collaboration and licensing agreement. We will update this record as details become available.
Bluebird Bio and Medigene
In September 2016, Medigene and bluebird bio announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies against four targets.
Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following the collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates and will receive an exclusive license for the intellectual property covering the resulting TCRs.
Medigene will receive an upfront payment of USD 15 million as well as potential preclinical, clinical, regulatory and commercial milestone payments, which together could total over USD 1 billion in the aggregate for the four potential TCR products across several indications. Additionally,...See full deal structure in Biomedtracker
Partners: MediGene AG
Bluebird-Medigene TCR Candidate News
Additional information available to subscribers only: